OncLive Insights

Panelists discuss how genetic testing and RET-targeted therapies play a crucial role in guiding the treatment of advanced NSCLC, with a focus on optimizing first-line therapy and managing challenges in molecular testing and treatment sequencing.

Jorge Cortes, MD, and Stephen A. Strickland Jr, MD, MSCI,discuss how in the management of chronic myeloid leukemia (CML), clinicians must carefully monitor early treatment response milestones with first-line tyrosine kinase inhibitor therapy, consider appropriate switching strategies including BCR::ABL1 mutation testing, and select between newer agents such as asciminib and ponatinib based on patient-specific factors, trial data, and distinct safety profiles, particularly regarding cardiovascular toxicities.

Panelists discuss how recent advancements in ovarian cancer treatment, including biomarker-guided therapy, PARP inhibitors, combination therapies, and antibody-drug conjugates, are shaping personalized management strategies to improve patient outcomes.

Panelists discuss how emerging treatment strategies, including the use of CDK4/6 inhibitors and personalized risk stratification, are transforming the management of high-risk HR+/HER2– early-stage breast cancer, emphasizing the importance of multidisciplinary care and patient-specific approaches.

Panelists discuss optimizing treatment strategies for higher-risk myelofibrosis patients. They focus on managing thrombocytopenia, anemia, and ruxolitinib failure while exploring the role of JAK inhibitors and sequencing therapies.

Panelists discuss how the management of lung large cell neuroendocrine carcinoma (LCNEC) involves a multidisciplinary approach, focusing on molecular characterization, biomarker testing, and emerging treatment options, including novel targeted therapies and ongoing clinical trials.

Panelists discuss how current third-line treatment options for metastatic colorectal cancer, including regorafenib, trifluridine-tipiracil plus bevacizumab, and fruquintinib, are selected based on patient-specific factors, safety profiles, and treatment goals, while also exploring future directions and unmet needs in mCRC management.

Elizabeth O’Donnell, MD, discusses how recent clinical trial findings are reshaping frontline treatment strategies for transplant-ineligible patients with newly diagnosed multiple myeloma, emphasizing the importance of patient-specific factors in therapy selection.

Furthermore, Douglas Sborov, MD, discusses how recent advancements in clinical trials and treatment strategies are reshaping the management of newly diagnosed multiple myeloma patients who are eligible for transplant.

Thomas Powles, MBBS, MRCP, MD, discusses currently available treatment options for previously untreated locally advanced and metastatic urothelial cancer. He presents a hypothetical clinical scenario and discusses his treatment approach to illustrate how he incorporates recent data into his clinical practice.

Margaret Kasner, MD, and Christian Fidler, MD, discuss how effective management of secondary acute myeloid leukemia (AML) in community settings requires early diagnosis, accurate risk stratification, timely referrals, personalized treatment approaches, robust supportive care, and close collaboration with academic centers to ensure optimal patient outcomes.

Panelists discuss how targeted therapies and effective management of adverse events, particularly in relation to the PI3K/AKT/PTEN pathway, are crucial for optimizing treatment outcomes in hormone receptor (HR)–positive, HER2-negative advanced breast cancer.

Nitin Jain, MD, and Joanna M. Rhodes, MD, MDCS, discuss how various aspects of chronic lymphocytic leukemia (CLL) management are approached, including treatment selection based on prior therapies and patient factors, the use of novel agents such as pirtobrutinib, strategies for relapsed/refractory (R/R) disease, treatment sequencing, and the role of multidisciplinary teams in optimizing patient care and outcomes.

Panelists discuss how recent advances in treating Lower-Risk Myelodysplastic Syndromes have impacted clinical practice, using hypothetical scenarios to demonstrate their approach to incorporating new data into patient care.

Panelists discuss how advancements in biomarker and genetic testing, along with updated treatment guidelines, are transforming the diagnosis and management of prostate cancer, emphasizing the importance of personalized approaches in optimizing patient outcomes.

Hope Rugo, MD, FASCO and Aditya Bardia MD, MPH, FASCOexplore strategies for managing antibody drug conjugate (ADC)-related toxicities in breast cancer, covering current ADCs, real-world management practices, and future directions, in this OncLive Insights video series.

This educational program, led by experts Shernan Holtan, MD, and Haris Ali, MD, explores the latest strategies and emerging treatments for optimizing management of chronic graft-vs-host disease (cGVHD), including monitoring techniques, therapeutic options, and patient-reported outcomes.

A panel of experts on nasopharyngeal carcinoma review patient cases and provide comprehensive insights on treatment practices.

Robert Z. Orlowski, MD, PhD, and Jonathan Kaufman, MD, Leading experts in relapsed/refractory multiple myeloma, explore evolving treatment landscapes, including CAR T-cell therapies, the role of selinexor, and optimized sequencing strategies, while addressing two complex clinical scenarios and providing key insights for community oncologists to enhance patient care.

Experts on adolescent and young adult acute lymphoblastic leukemia review patient cases have a comprehensive discussion on treatment practices and the evolving therapeutic landscape.

Pediatric low-grade glioma specialists examine recent therapeutic advancements and their practical implications, presenting two real-world cases to demonstrate the integration of new data into clinical decision-making.

Hannah Choe, MD discusses the role of the CSF-1 receptor (CSF-1R) pathway in the pathogenesis of graft-versus-host disease (GVHD) and other diseases. She reviews the rationale for targeting this pathway as a therapeutic strategy and examines preclinical and clinical data on the use of CSF-1R inhibitors, such as axatilimab, for the treatment of GVHD. Dr. Choe provides insights on the practical considerations for integrating these novel agents into clinical practice.

Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, examine the role of androgen receptor inhibitors, emphasize the significance of early intervention and biomarkers, and evaluate recent developments in the treatment paradigm for castration-sensitive prostate cancer.

A panel of experts on chronic lymphocytic leukemia review patient cases, discuss the latest research presented at ASCO 2024 and surrounding meetings, and provide insights on evolving clinical practices.

Martin H. Voss, MD, and Moshe Ornstein, MD, explore non-clear cell renal cell carcinoma and the potential impact of clinical trials on the evolution of treatment approaches.

Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, explore the evolving landscape of HR+/HER2- metastatic breast cancer management, focusing on the clinical implications of ESR1 and PIK3CA mutations, the role of biomarker testing, the impact of novel therapies and combination strategies, and the importance of personalized treatment approaches in improving patient outcomes.

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, provide valuable insights into targeting the PI3K/AKT/PTEN pathway, exploring mechanisms of resistance, adverse event profiles, and treatment decision-making strategies for patients with HR+/HER2- locally advanced and metastatic breast cancer.

Nathalie Albert, MD, and Matthias Preusser, MD, explore the latest advancements in neuroimaging technologies and techniques, focusing on the use of amino acid tracers to enhance the diagnosis, treatment, and overall care of patients with glioblastoma.

Tiffany A. Traina, MD; Vijayakrishna Gadi, MD, PhD, and Heather McArthur, MD, explore the current treatment landscape for HER2-positive metastatic breast cancer. They discuss standard of care therapies across lines, pivotal trial data, management of brain metastases, optimal sequencing strategies after, and emerging novel agents. Two patient cases help illustrate real-world decision-making.